MPH MPH - POINT Biopharma Ex Devel
| PNTDelisted Stock | USD 12.50 0.00 0.00% |
Insider
MPH MPH is Ex Devel of POINT Biopharma Global
| Age | 42 |
| Phone | 647 812 2417 |
| Web | https://www.pointbiopharma.com |
POINT Biopharma Management Efficiency
The company has Return on Asset of 0.1677 % which means that on every $100 spent on assets, it made $0.1677 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.2633 %, implying that it generated $0.2633 on every 100 dollars invested. POINT Biopharma's management efficiency ratios could be used to measure how well POINT Biopharma manages its routine affairs as well as how well it operates its assets and liabilities.The company has 3.56 M in debt with debt to equity (D/E) ratio of 0.01, which may show that the company is not taking advantage of profits from borrowing. POINT Biopharma Global has a current ratio of 10.68, demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due. Debt can assist POINT Biopharma until it has trouble settling it off, either with new capital or with free cash flow. So, POINT Biopharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like POINT Biopharma Global sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for POINT to invest in growth at high rates of return. When we think about POINT Biopharma's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Linda Fitzpatrick | Sutro Biopharma | 67 | |
| Karen Anderson | Centessa Pharmaceuticals PLC | 56 | |
| Deepika PharmD | Pmv PharmaceuticalsInc | 47 | |
| Chris JD | Alx Oncology Holdings | N/A | |
| George Eldridge | Aerovate Therapeutics | 61 | |
| Natalie Holles | Third Harmonic Bio | 51 | |
| Path FRCP | Revolution Medicines | 61 | |
| Rodney Young | RAPT Therapeutics | 61 | |
| Michael Carruthers | Edgewise Therapeutics | 66 | |
| Philippe Martin | BioatlaInc | 48 | |
| BS CPA | InhibrxInc | 42 | |
| Peter MBA | Alx Oncology Holdings | 62 | |
| Richard Waldron | BioatlaInc | 70 | |
| CMA CPA | ESSA Pharma | 65 | |
| Donna Dea | Aerovate Therapeutics | N/A | |
| Astrid MD | Hillevax | 54 | |
| MD MBA | Opthea | N/A | |
| Leila MD | Pmv PharmaceuticalsInc | 61 | |
| Kevin Capps | Crinetics Pharmaceuticals | N/A | |
| Toni Weinschenk | Immatics NV | 50 | |
| James Goding | Opthea | N/A | |
Management Performance
| Return On Equity | 0.26 | |||
| Return On Asset | 0.17 |
POINT Biopharma Global Leadership Team
Elected by the shareholders, the POINT Biopharma's board of directors comprises two types of representatives: POINT Biopharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of POINT. The board's role is to monitor POINT Biopharma's management team and ensure that shareholders' interests are well served. POINT Biopharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, POINT Biopharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| MPH MPH, Ex Devel | ||
| FRCSC MD, Chief Director | ||
| Ari Shomair, VP Staff | ||
| Joe McCann, CEO Director | ||
| Donna BA, VP HR | ||
| RPh Herle, Ex Affairs | ||
| BBA FCA, Chief Officer | ||
| Todd BE, Ex Operations | ||
| Justyna MSc, Chief Officer | ||
| Allan Silber, Ex Chairman | ||
| Dr JD, Sr Devel |
POINT Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is POINT Biopharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.26 | |||
| Return On Asset | 0.17 | |||
| Profit Margin | 0.40 % | |||
| Operating Margin | (10.62) % | |||
| Current Valuation | 1 B | |||
| Shares Outstanding | 106.57 M | |||
| Shares Owned By Insiders | 14.97 % | |||
| Shares Owned By Institutions | 48.91 % | |||
| Number Of Shares Shorted | 2.64 M | |||
| Price To Book | 3.13 X |
Pair Trading with POINT Biopharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if POINT Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in POINT Biopharma will appreciate offsetting losses from the drop in the long position's value.Moving against POINT Stock
| 0.65 | BA | Boeing Financial Report 24th of July 2024 | PairCorr |
| 0.45 | INTC | Intel Financial Report 25th of July 2024 | PairCorr |
The ability to find closely correlated positions to POINT Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace POINT Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back POINT Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling POINT Biopharma Global to buy it.
The correlation of POINT Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as POINT Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if POINT Biopharma Global moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for POINT Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Other Consideration for investing in POINT Stock
If you are still planning to invest in POINT Biopharma Global check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the POINT Biopharma's history and understand the potential risks before investing.
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios |